Lornoxicam Sustained Release Tablets | Long-Lasting Pain Relief

Therapeutic Indication

Chronic pain management

Osteoarthritis

Rheumatoid arthritis

Chronic musculoskeletal pain

Long-term inflammatory conditions

+91 85919 78885

Lornoxicam Sustained Release

Tablet

Lornoxicam Sustained Release (SR) tablets are designed to provide prolonged pain relief with a controlled release of the active ingredient over time. It belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) and is used to reduce pain, inflammation, and stiffness. The sustained release formulation ensures longer duration of action, reducing the need for frequent dosing and improving patient compliance, especially in chronic conditions like arthritis. It is ideal for patients requiring continuous pain management and should be taken strictly under medical supervision.

Speciality	Long-Acting NSAID
Tags	Pain Relief \| Anti-inflammatory \| Sustained Release
Strength	8 mg 12 mg 16 mg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Lornoxicam inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. The sustained release formulation allows gradual drug release, ensuring prolonged anti-inflammatory and analgesic effects.

Pharmacokinetics

Absorption: Slower, controlled absorption due to sustained release formulation.
Distribution: Highly protein bound.
Metabolism: Metabolized in liver via CYP2C9.
Elimination: Excreted through urine and feces.

Side Effects

Gastric irritation
Nausea
Dizziness
Headache
Rarely gastrointestinal bleeding

Contraindication

Peptic ulcer disease
Severe hepatic or renal impairment
Hypersensitivity to NSAIDs

Interaction

Anticoagulants (increased bleeding risk)
Diuretics (reduced efficacy)
ACE inhibitors
Methotrexate (increased toxicity)

Warning and Precautions

Use lowest effective dose
Monitor GI, kidney, and liver function
Avoid long-term unsupervised use
Not recommended in pregnancy